- Home
- NXTC
NXTC
NextCure Inc.
as 07-26-2024 4:00pm EST
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Upcoming Earnings Alert:
Get ready for potential market movements as NextCure Inc. NXTC prepares to release earnings report on 01 Aug 2024.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BELTSVILLE |
| Market Cap: | 45.0M | IPO Year: | 2019 |
| Target Price: | $6.00 | AVG Volume (30 days): | 57.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $2.57 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NextCure Inc. News
NXTC Breaking Stock News: Dive into NXTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GlobeNewswire
2 months ago
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
GlobeNewswire
3 months ago
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
3 months ago
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
GlobeNewswire
4 months ago
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
GlobeNewswire
4 months ago
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
GlobeNewswire
4 months ago
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
Simply Wall St.
4 months ago
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Compare NXTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXTC NextCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.